These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34399038)

  • 1. IL-10 Receptor Neutralization-Induced Colitis in Mice: A Comprehensive Guide.
    Saha P; Golonka RM; Abokor AA; Yeoh BS; Vijay-Kumar M
    Curr Protoc; 2021 Aug; 1(8):e227. PubMed ID: 34399038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data on IL-10R neutralization-induced chronic colitis in Lipocalin 2 deficient mice on BALB/c background.
    Singh V; Yeoh BS; Nilsen-Hamilton M; Berger T; Mak TW; Vijay-Kumar M
    Data Brief; 2017 Apr; 11():588-592. PubMed ID: 28349107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1β (IL-1β) promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis.
    Carvalho FA; Nalbantoglu I; Ortega-Fernandez S; Aitken JD; Su Y; Koren O; Walters WA; Knight R; Ley RE; Vijay-Kumar M; Gewirtz AT
    Gut; 2012 Mar; 61(3):373-84. PubMed ID: 21646247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Infection of the Central Nervous System Exacerbates Interleukin-10 Receptor Deficiency-Mediated Colitis in SJL Mice.
    Uhde AK; Herder V; Akram Khan M; Ciurkiewicz M; Schaudien D; Teich R; Floess S; Baumgärtner W; Huehn J; Beineke A
    PLoS One; 2016; 11(9):e0161883. PubMed ID: 27611574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
    Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
    BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease.
    Karmele EP; Pasricha TS; Ramalingam TR; Thompson RW; Gieseck RL; Knilans KJ; Hegen M; Farmer M; Jin F; Kleinman A; Hinds DA; ; Almeida Pereira T; de Queiroz Prado R; Bing N; Tchistiakova L; Kasaian MT; Wynn TA; Vannella KM
    Mucosal Immunol; 2019 Sep; 12(5):1174-1186. PubMed ID: 31308480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental colitis in IL-10-deficient mice ameliorates in the absence of PTPN22.
    Jofra T; Galvani G; Cosorich I; De Giorgi L; Annoni A; Vecchione A; Sorini C; Falcone M; Fousteri G
    Clin Exp Immunol; 2019 Sep; 197(3):263-275. PubMed ID: 31194881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy.
    Kotlarz D; Beier R; Murugan D; Diestelhorst J; Jensen O; Boztug K; Pfeifer D; Kreipe H; Pfister ED; Baumann U; Puchalka J; Bohne J; Egritas O; Dalgic B; Kolho KL; Sauerbrey A; Buderus S; Güngör T; Enninger A; Koda YK; Guariso G; Weiss B; Corbacioglu S; Socha P; Uslu N; Metin A; Wahbeh GT; Husain K; Ramadan D; Al-Herz W; Grimbacher B; Sauer M; Sykora KW; Koletzko S; Klein C
    Gastroenterology; 2012 Aug; 143(2):347-55. PubMed ID: 22549091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental mouse models of T cell-dependent inflammatory bowel disease.
    Song-Zhao GX; Maloy KJ
    Methods Mol Biol; 2014; 1193():199-211. PubMed ID: 25151008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice.
    Keates AC; Castagliuolo I; Cruickshank WW; Qiu B; Arseneau KO; Brazer W; Kelly CP
    Gastroenterology; 2000 Oct; 119(4):972-82. PubMed ID: 11040184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse--a model mimicking inflammatory bowel disease.
    Holgersen K; Kvist PH; Markholst H; Hansen AK; Holm TL
    J Crohns Colitis; 2014 Feb; 8(2):147-60. PubMed ID: 23994255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proneness of TLR5 deficient mice to develop colitis is microbiota dependent.
    Singh V; Yeoh BS; Carvalho F; Gewirtz AT; Vijay-Kumar M
    Gut Microbes; 2015 Jul; 6(4):279-83. PubMed ID: 26067589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
    van Hogezand RA; Verspaget HW
    Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis.
    Moran CJ; Walters TD; Guo CH; Kugathasan S; Klein C; Turner D; Wolters VM; Bandsma RH; Mouzaki M; Zachos M; Langer JC; Cutz E; Benseler SM; Roifman CM; Silverberg MS; Griffiths AM; Snapper SB; Muise AM
    Inflamm Bowel Dis; 2013 Jan; 19(1):115-23. PubMed ID: 22550014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-23-producing IL-10Rα-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response.
    Bernshtein B; Curato C; Ioannou M; Thaiss CA; Gross-Vered M; Kolesnikov M; Wang Q; David E; Chappell-Maor L; Harmelin A; Elinav E; Thakker P; Papayannopoulos V; Jung S
    Sci Immunol; 2019 Jun; 4(36):. PubMed ID: 31201258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis.
    Patik I; Redhu NS; Eran A; Bao B; Nandy A; Tang Y; El Sayed S; Shen Z; Glickman J; Fox JG; Snapper SB; Horwitz BH
    Mucosal Immunol; 2023 Jun; 16(3):233-249. PubMed ID: 36868479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?
    Shen C; de Hertogh G; Bullens DM; Van Assche G; Geboes K; Rutgeerts P; Ceuppens JL
    Inflamm Bowel Dis; 2007 Mar; 13(3):308-16. PubMed ID: 17206708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
    Colombo G; Clemente N; Zito A; Bracci C; Colombo FS; Sangaletti S; Jachetti E; Ribaldone DG; Caviglia GP; Pastorelli L; De Andrea M; Naviglio S; Lucafò M; Stocco G; Grolla AA; Campolo M; Casili G; Cuzzocrea S; Esposito E; Malavasi F; Genazzani AA; Porta C; Travelli C
    J Mol Med (Berl); 2020 Apr; 98(4):595-612. PubMed ID: 32338310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication.
    Singh UP; Venkataraman C; Singh R; Lillard JW
    Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):111-23. PubMed ID: 17584151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
    Igaki K; Nakamura Y; Tanaka M; Mizuno S; Yoshimatsu Y; Komoike Y; Uga K; Shibata A; Imaichi H; Takayuki S; Ishimura Y; Yamasaki M; Kanai T; Tsukimi Y; Tsuchimori N
    Inflamm Res; 2019 Jun; 68(6):493-509. PubMed ID: 30972425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.